Chinese a Nti鄄 Cancer a Ssociation

Breast cancer resistance protein (BCRP)/ATP-binding cassette subfamily G member 2 (ABCG2) is an ATP-binding cassette (ABC) transporter identified as a molecular cause of multidrug resistance (MDR) in diverse cancer cells. BCRP physiologically functions as a part of a self-defense mechanism for the organism; it enhances elimination of toxic xenobiotic substances and harmful agents in the gut and biliary tract, as well as through the blood-brain, placental, and possibly blood-testis barriers. BCRP recognizes and transports numerous anticancer drugs including conventional chemotherapeutic and targeted small therapeutic molecules relatively new in clinical use. Thus, BCRP expression in cancer cells directly causes MDR by active efflux of anticancer drugs. Because BCRP is also known to be a stem cell marker, its expression in cancer cells could be a manifestation of metabolic and signaling pathways that confer multiple mechanisms of drug resistance, self-renewal (sternness), and invasiveness (aggressiveness), and thereby impart a poor prognosis. Therefore, blocking BCRP-mediated active efflux may provide a therapeutic benefit for cancers. Delineating the precise molecular mechanisms for BCRP gene expression may lead to identification of a novel molecular target to modulate BCRP-mediated MDR. Current evidence suggests that BCRP gene transcription is regulated by a number of trans-acting elements including hypoxia inducible factor 1α, estrogen receptor, and peroxisome proliferator-activated receptor. Furthermore, alternative promoter usage, demethylation of the BCRP promoter, and histone modification are likely associated with drug-induced BCRP overexpression in cancer cells. Finally, PI3K/AKT signaling may play a critical role in modulating BCRP function under a variety of conditions. These biological events seem involved in a complicated manner. Untangling the events would be an essential first step to developing a method to modulate BCRP function to aid patients with cancer. This review will present a synopsis of the impact of BCRP-mediated MDR in cancer cells, and the molecular mechanisms of acquired MDR currently postulated in a variety of human cancers.

[1]  E. Shin,et al.  Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer , 2007, Cancer.

[2]  L. Doyle,et al.  Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. , 2001, Biochimica et biophysica acta.

[3]  Daniel J Garry,et al.  Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. , 2004, Developmental biology.

[4]  E. Barta,et al.  Peroxisome Proliferator-activated Receptor γ-regulated ABCG2 Expression Confers Cytoprotection to Human Dendritic Cells* , 2006, Journal of Biological Chemistry.

[5]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[6]  D. Ross,et al.  Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. , 2006, Blood.

[7]  R. Kim,et al.  Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants , 2007, Pharmacogenetics and genomics.

[8]  D. Sullivan,et al.  Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. , 2006, Cancer research.

[9]  Martin G. Pomper,et al.  Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. , 2009, Cancer research.

[10]  C. Hrycyna,et al.  N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. , 2005, Biochemistry.

[11]  R. Robey,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. , 2008, Cancer research.

[12]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[13]  G. Superti-Furga,et al.  Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib. , 2007 .

[14]  M. Raaijmakers,et al.  Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38− Cells in Acute Myeloid Leukemia , 2005, Clinical Cancer Research.

[15]  T. Ishikawa,et al.  Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro , 2009, Pharmaceutical Research.

[16]  Jos H Beijnen,et al.  Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration , 2012, International journal of cancer.

[17]  I. Shiojima,et al.  Akt Signaling Regulates Side Population Cell Phenotype via Bcrp1 Translocation* , 2003, Journal of Biological Chemistry.

[18]  U. Völker,et al.  EPIDERMAL GROWTH FACTOR-MEDIATED ACTIVATION OF THE MAP KINASE CASCADE RESULTS IN ALTERED EXPRESSION AND FUNCTION OF ABCG2 (BCRP) , 2006, Drug Metabolism and Disposition.

[19]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[20]  J. Ware,et al.  Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse , 2006, Molecular pharmaceutics.

[21]  T. Ishikawa,et al.  Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation. , 2009, Advanced drug delivery reviews.

[22]  S. Bates,et al.  Aberrant Promoter Methylation of the ABCG2 Gene in Renal Carcinoma , 2006, Molecular and Cellular Biology.

[23]  H. Nakauchi.  Isolation and Clonal Characterization of Hematopoietic and Liver Stem Cells , 2004, Cornea.

[24]  M. B. Davis,et al.  breast cancer cells , 2009 .

[25]  Y. Wang,et al.  Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells , 2007, Leukemia.

[26]  T. Fojo,et al.  Increased MDR 1 Expression in Normal andMalignant Peripheral BloodMononuclear Cells Obtained from Patients Receiving Depsipeptide ( FR 901228 , FK 228 , NSC 630176 ) , 2006 .

[27]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[28]  M. Pomper,et al.  ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. , 2007, Cancer research.

[29]  J. Schellens,et al.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.

[30]  Y. Assaraf,et al.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. , 2009, Neoplasia.

[31]  Y. Sugimoto,et al.  Gefitinib reverses breast cancer resistance protein-mediated drug resistance. , 2004, Molecular cancer therapeutics.

[32]  Yi Zhang,et al.  Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. , 2006, American journal of physiology. Endocrinology and metabolism.

[33]  B. Dijkmans,et al.  Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFα , 2004, Annals of the rheumatic diseases.

[34]  T. Litman,et al.  Identification of Intra- and Intermolecular Disulfide Bridges in the Multidrug Resistance Transporter ABCG2* , 2005, Journal of Biological Chemistry.

[35]  I. Pastan,et al.  Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. , 1987, The Journal of biological chemistry.

[36]  A. Calcagno,et al.  Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor , 2006, Molecular Cancer Therapeutics.

[37]  D. Ross,et al.  Impact of breast cancer resistance protein on cancer treatment outcomes. , 2010, Methods in molecular biology.

[38]  Joseph W. Polli,et al.  An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.

[39]  M. Pirmohamed,et al.  Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters , 2009, Leukemia.

[40]  E. Rego,et al.  Determination of P‐glycoprotein, MDR‐related protein 1, breast cancer resistance protein, and lung‐resistance protein expression in leukemic stem cells of acute myeloid leukemia , 2008, Cytometry. Part B, Clinical cytometry.

[41]  H. Berenbaum,et al.  Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. , 2006, Blood.

[42]  T. Powles,et al.  A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRP , 2010, Molecular Cancer Therapeutics.

[43]  T. Ishikawa,et al.  Disruption of N‐linked glycosylation enhances ubiquitin‐mediated proteasomal degradation of the human ATP‐binding cassette transporter ABCG2 , 2009, The FEBS journal.

[44]  Hong-Bin Fang,et al.  Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. , 2003, Molecular pharmacology.

[45]  Q. Zhu,et al.  Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin. , 1994, Cancer research.

[46]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[47]  J. Meijerink,et al.  Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) , 2002, Leukemia.

[48]  Jos H. Beijnen,et al.  Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation , 2010, Molecular Cancer Therapeutics.

[49]  Shusen Zheng,et al.  Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. , 2008, Carcinogenesis.

[50]  Yuichi Sugiyama,et al.  Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans , 2008, Clinical pharmacology and therapeutics.

[51]  V. P. Savitski,et al.  CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34− cells in childhood AML , 2008, Annals of Hematology.

[52]  David S. Miller,et al.  17-β-Estradiol: A Powerful Modulator of Blood–Brain Barrier BCRP Activity , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[53]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[54]  S. Bates,et al.  Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. , 2002, Blood.

[55]  Mariël Brok,et al.  Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.

[56]  Sagar Agarwal,et al.  The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain , 2011, Journal of Pharmacology and Experimental Therapeutics.

[57]  T. Utsunomiya,et al.  Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System , 2006, Stem cells.

[58]  P. Sonneveld,et al.  CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age , 2007, Annals of Hematology.

[59]  Jian-hua Chang,et al.  BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. , 2007, Carcinogenesis.

[60]  D. Rigal,et al.  Transcriptional Regulation of the Human MDR1 Gene at the Level of the Inverted MED‐1 Promoter Region , 2002, Annals of the New York Academy of Sciences.

[61]  R. Fanin,et al.  The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. , 2006, Haematologica.

[62]  O. van Tellingen,et al.  Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. , 2003, Cancer research.

[63]  T. Tsuruo,et al.  Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. , 2003, Molecular cancer therapeutics.

[64]  S. Rabindran,et al.  Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. , 1998, Cancer research.

[65]  T. Ince,et al.  Differential utilization of multiple transcription start points accompanies the overexpression of the P-glycoprotein-encoding gene in Chinese hamster lung cells. , 1995, Gene.

[66]  T. Ince,et al.  A Conserved Downstream Element Defines a New Class of RNA Polymerase II Promoters (*) , 1995, Journal of Biological Chemistry.

[67]  K. Iseki,et al.  Expression Level of ABCG2 in the Placenta Decreases from the Mid Stage to the End of Gestation , 2005, Bioscience, biotechnology, and biochemistry.

[68]  Francisco Gamarro,et al.  Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. , 2005, Cancer research.

[69]  O. Legrand,et al.  Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.

[70]  H. Minderman,et al.  Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023 , 2004, Cancer Chemotherapy and Pharmacology.

[71]  E. Schuetz,et al.  Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.

[72]  A. Reichel,et al.  N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[73]  J. Schuetz,et al.  The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme* , 2004, Journal of Biological Chemistry.

[74]  N. Shaik,et al.  P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib , 2009, Journal of Pharmacology and Experimental Therapeutics.

[75]  J. Rubnitz,et al.  Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. , 2011, Leukemia research.

[76]  L. Doyle,et al.  Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. , 2000, Cancer research.

[77]  A. Schinkel,et al.  Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. , 2011, Molecular pharmaceutics.

[78]  R. Marks,et al.  Squamous cell carcinoma , 1996, The Lancet.

[79]  P. Leung,et al.  Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells , 2008, Molecular Pharmacology.

[80]  T. Fojo,et al.  Amplification of 4q21–q22 and the MXR gene in independently derived mitoxantrone‐resistant cell lines , 2000, Genes, chromosomes & cancer.

[81]  A. V. van Herwaarden,et al.  Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. , 2006, Carcinogenesis.

[82]  M. Ballmaier,et al.  Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line , 2007, Molecular and Cellular Biochemistry.

[83]  K. Noguchi,et al.  Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. , 2009, Advanced drug delivery reviews.

[84]  T. Tsuruo,et al.  Dominant‐negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S‐S dependent homodimerization , 2002, International journal of cancer.

[85]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[86]  J. Mohler,et al.  Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. , 2005, Cancer research.

[87]  C. D. Salcido,et al.  Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes , 2008, British Journal of Cancer.

[88]  F. Segal,et al.  A CHARACTERIZATION OF FIBRANT SEGAL CATEGORIES , 2006, math/0603400.

[89]  C. Higgins,et al.  The ABC of channel regulation , 1995, Cell.

[90]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[91]  J. Schellens,et al.  Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications , 2000, Annals of the New York Academy of Sciences.

[92]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[93]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  Thomas Ried,et al.  Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2 , 2009, Molecular Cancer Therapeutics.

[95]  T. Ishikawa,et al.  Re‐evaluation and functional classification of non‐synonymous single nucleotide polymorphisms of the human ATP‐binding cassette transporter ABCG2 , 2007, Cancer science.

[96]  L. M. Wang,et al.  Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. , 2010, Mini reviews in medicinal chemistry.

[97]  S. Steinberg,et al.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  T. Litman,et al.  Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. , 2001, Biochemical and biophysical research communications.

[99]  M. Gasparetto,et al.  Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.

[100]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[101]  A. Fojo,et al.  Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. , 1990, The Journal of biological chemistry.

[102]  Zhe-Sheng Chen,et al.  Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. , 2009, Biochemical pharmacology.

[103]  G. Alí,et al.  Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. , 2011, Neoplasia.

[104]  J. Keelan,et al.  Independent Regulation of Apical and Basolateral Drug Transporter Expression and Function in Placental Trophoblasts by Cytokines, Steroids, and Growth Factors , 2007, Drug Metabolism and Disposition.

[105]  T. Janvilisri,et al.  Sterol Transport by the Human Breast Cancer Resistance Protein (ABCG2) Expressed in Lactococcus lactis* , 2003, Journal of Biological Chemistry.

[106]  I. Catalá,et al.  Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.

[107]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[108]  S. Baker,et al.  Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters , 2009, Clinical Cancer Research.

[109]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[110]  D. B. Duignan,et al.  A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. , 2006, Molecular pharmaceutics.

[111]  S H Kaufmann,et al.  The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. , 2001, Cancer research.

[112]  Stephen Lam,et al.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. , 2007, Cancer research.

[113]  G. Kéri,et al.  Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). , 2005, Cancer research.

[114]  H. Kusuhara,et al.  Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1. , 2011, Biochemical and biophysical research communications.

[115]  Yuichi Sugiyama,et al.  ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* , 2003, Journal of Biological Chemistry.

[116]  Jos H Beijnen,et al.  Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics , 2011, Drug Metabolism and Disposition.

[117]  Xin Li,et al.  Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. , 2011, Biochemical pharmacology.

[118]  T. Ishikawa,et al.  Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. , 2001, Biochemical and biophysical research communications.

[119]  H. Aburatani,et al.  Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells , 2011, Oncogene.

[120]  Rudolf Jaenisch,et al.  Ectopic Expression of Oct-4 Blocks Progenitor-Cell Differentiation and Causes Dysplasia in Epithelial Tissues , 2005, Cell.

[121]  A. Schinkel,et al.  Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). , 2002, Molecular cancer therapeutics.

[122]  Linhao Li,et al.  A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. , 2010, Biochemical pharmacology.

[123]  Yehuda G. Assaraf,et al.  Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates , 2006, Cancer Chemotherapy and Pharmacology.

[124]  F. Zunino,et al.  Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. , 2007, Biochemical pharmacology.

[125]  M. Wierdl,et al.  Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. , 2003, Molecular pharmacology.

[126]  W. T. Beck,et al.  Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene , 2004, Cancer Research.

[127]  E. Giovannetti,et al.  Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco‐2 cells , 2008, International journal of cancer.

[128]  Sharon Marsh,et al.  Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype , 2004, Clinical pharmacology and therapeutics.

[129]  A. S. Conner,et al.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo , 1996, The Journal of experimental medicine.

[130]  B. Leyland-Jones,et al.  Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling , 2010, British Journal of Cancer.

[131]  Fei Li,et al.  Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. , 2002, Cancer research.

[132]  L. Doyle,et al.  Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. , 2000, Blood.

[133]  A. Masamune,et al.  The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2 , 2012, Journal of cellular physiology.

[134]  Ruoping Tang,et al.  MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia , 2005, Clinical Cancer Research.

[135]  F. Morabito,et al.  Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. , 2004, Leukemia research.

[136]  Jing Li,et al.  Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients , 2007, Cancer biology & therapy.

[137]  M. Lübbert,et al.  Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes , 2009, Clinical Cancer Research.

[138]  I. Hidalgo,et al.  Application and limitation of inhibitors in drug-transporter interactions studies. , 2008, International journal of pharmaceutics.

[139]  Alexei A. Sharov,et al.  Dissecting Oct3/4-Regulated Gene Networks in Embryonic Stem Cells by Expression Profiling , 2006, PloS one.

[140]  D. Miller,et al.  Estrogen Receptor β Signaling through Phosphatase and Tensin Homolog/Phosphoinositide 3-Kinase/Akt/Glycogen Synthase Kinase 3 Down-Regulates Blood-Brain Barrier Breast Cancer Resistance Protein , 2010, Journal of Pharmacology and Experimental Therapeutics.

[141]  M. Tan,et al.  Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[142]  Suneet Shukla,et al.  Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. , 2011, Molecular pharmaceutics.

[143]  E. Henderson,et al.  Lymphoblastic leukaemia. , 1969, British medical journal.

[144]  W. Kamps,et al.  The role of breast cancer resistance protein in acute lymphoblastic leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[145]  Y. Miki,et al.  C 421 A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q 141 K Protein and Low-Level Drug Resistance 1 , 2002 .

[146]  S. Emanuel,et al.  The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. , 2005, Cancer research.

[147]  L. Doyle,et al.  Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. , 1996, Leukemia.

[148]  Hui Peng,et al.  A Novel Two Mode-Acting Inhibitor of ABCG2-Mediated Multidrug Transport and Resistance in Cancer Chemotherapy , 2009, PloS one.

[149]  Hailong Wu,et al.  Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance Phenotype , 2010, Molecular Cancer Therapeutics.

[150]  Y. Miao,et al.  hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations , 2010, British Journal of Cancer.

[151]  M Dietel,et al.  Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. , 1999, Journal of the National Cancer Institute.

[152]  W. T. Beck,et al.  Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine. , 2011, Biochimica et biophysica acta.

[153]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[154]  F. S. Pardo,et al.  Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. , 2008, Archives of otolaryngology--head & neck surgery.

[155]  J. Verweij,et al.  Effect of ABCG2 genotype on the oral vioavailability of topotecan , 2005, Cancer biology & therapy.

[156]  G. Szakács,et al.  Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.

[157]  Jing Wang,et al.  Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. , 2009, Stem cells and development.

[158]  W. Greco,et al.  Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function , 2004, Leukemia.

[159]  N. Sundarraj,et al.  Multipotent Stem Cells in Human Corneal Stroma , 2004, Stem cells.

[160]  D. Steinbach,et al.  Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia , 2002, British journal of haematology.

[161]  Peter J Houghton,et al.  Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice , 2004, Cancer Research.

[162]  X. Ronot,et al.  Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2). , 2005, Journal of medicinal chemistry.

[163]  Ha-won Jeong,et al.  SALL4, a Stem Cell Factor, Affects the Side Population by Regulation of the ATP-Binding Cassette Drug Transport Genes , 2011, PloS one.

[164]  I. Pastan,et al.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[165]  T. Fojo,et al.  Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) , 2006, Clinical Cancer Research.

[166]  S. Kohno,et al.  Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. , 2005, Cancer research.

[167]  J. Schellens,et al.  Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice , 2008, Molecular Cancer Therapeutics.

[168]  S. Bates,et al.  Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. , 2003, Cancer research.

[169]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[170]  H. Bartsch,et al.  Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients , 2009, International journal of cancer.

[171]  Yong-Hae Han,et al.  Involvement of P-glycoprotein, Multidrug Resistance Protein 2 and Breast Cancer Resistance Protein in the Transport of Belotecan and Topotecan in Caco-2 and MDCKII Cells , 2008, Pharmaceutical Research.

[172]  P. Watkins,et al.  Association of Breast Cancer Resistance Protein/ABCG2 Phenotypes and Novel Promoter and Intron 1 Single Nucleotide Polymorphisms , 2008, Drug Metabolism and Disposition.

[173]  Yasuaki Yamada,et al.  Expression and functional analyses of breast cancer resistance protein in lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[174]  S. Bates,et al.  Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2* , 2004, Journal of Biological Chemistry.

[175]  Suneet Shukla,et al.  Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2 , 2009, Drug Metabolism and Disposition.

[176]  Alfonso Lampen,et al.  Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. , 2005, Carcinogenesis.

[177]  S. Bates,et al.  Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells , 2008, Molecular Cancer Research.

[178]  P. Boutros,et al.  Aryl Hydrocarbon Receptor Is a Transcriptional Activator of the Human Breast Cancer Resistance Protein ( BCRP / ABCG 2 ) , 2010 .

[179]  Fang Wang,et al.  Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function , 2009, PloS one.

[180]  M. Leggas,et al.  Progesterone Acts via Progesterone Receptors A and B to Regulate Breast Cancer Resistance Protein Expression , 2008, Molecular Pharmacology.

[181]  V. Ling,et al.  MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. , 2008, Experimental hematology.

[182]  Eun-Young Kim,et al.  Identification and Functional Assessment of BCRP Polymorphisms in a Korean Population , 2007, Drug Metabolism And Disposition.

[183]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[184]  A. Zannettino,et al.  Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity , 2010, Leukemia.

[185]  Cynthia S. Johnson,et al.  Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis , 2006, Clinical Cancer Research.

[186]  H. Kotani,et al.  Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. , 2001, Cancer research.

[187]  J. Melo,et al.  Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.

[188]  Xiaokun Cai,et al.  Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. , 2010, International journal of biochemistry and molecular biology.

[189]  J. Wang-Rodriguez,et al.  EGFR Regulates the Side Population in Head and Neck Squamous Cell Carcinoma , 2006, The Laryngoscope.

[190]  J. DiMaio,et al.  Cellular and Molecular Regulation of Skeletal Muscle Side Population Cells , 2004, Stem cells.

[191]  Jiang Zhu,et al.  Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials , 2008, Journal of Cancer Research and Clinical Oncology.

[192]  B. Sorrentino,et al.  Expression of Mouse Abcg2 mRNA during Hematopoiesis Is Regulated by Alternative Use of Multiple Leader Exons and Promoters* , 2006, Journal of Biological Chemistry.

[193]  S. Bates,et al.  Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. , 2007, Cancer research.

[194]  S. Dhakshinamoorthy,et al.  Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. , 2000, Current topics in cellular regulation.

[195]  E. Kis,et al.  Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. , 2009, Biological & pharmaceutical bulletin.

[196]  H. Burris,et al.  Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. , 2004, The oncologist.

[197]  Ming-Rong Zhang,et al.  [11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. , 2011, Bioorganic & medicinal chemistry letters.

[198]  A. Hofman,et al.  Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study , 2008, The Lancet.

[199]  Y. Sugimoto,et al.  Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. , 2005, Cancer research.

[200]  J. Schellens,et al.  The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. , 2005, Cancer research.

[201]  M. Andreeff,et al.  Low levels of ABCG2 expression in adult AML blast samples. , 2002, Blood.

[202]  P. Lu,et al.  Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4–AKT–ATP‐binding cassette G2 pathway , 2010, Hepatology.

[203]  A. Seidel,et al.  Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[204]  B. Luo,et al.  A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. , 2009, Neoplasma.

[205]  Y. Sugiyama,et al.  REGULATION OF THE CELL SURFACE EXPRESSION OF HUMAN BCRP/ABCG2 BY THE PHOSPHORYLATION STATE OF AKT IN POLARIZED CELLS , 2005, Drug Metabolism and Disposition.

[206]  M. Goodell,et al.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[207]  F. Boussin,et al.  Neural stem cells from mouse forebrain are contained in a population distinct from the ‘side population’ , 2006, Journal of neurochemistry.

[208]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[209]  S. Bates,et al.  Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway , 2011, Molecular Cancer Research.

[210]  Sagar Agarwal,et al.  Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux , 2010, Journal of Pharmacology and Experimental Therapeutics.

[211]  K. Kondo,et al.  Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8 , 2002, Journal of Human Genetics.

[212]  Shaoxiang Zhang,et al.  MicroRNAs play a role in the development of human hematopoietic stem cells , 2008, Journal of cellular biochemistry.

[213]  Fang Wang,et al.  Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. , 2010, Cancer research.

[214]  K. Motojima,et al.  PPARα Agonists Positively and Negatively Regulate the Expression of Several Nutrient/Drug Transporters in Mouse Small Intestine , 2007 .

[215]  T. Ishikawa,et al.  Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system. , 2006, Journal of experimental therapeutics & oncology.

[216]  S. Bates,et al.  Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib , 2010, Drug Metabolism and Disposition.